Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan Sullivan

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumorsFlorentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.
Frontiers in Oncology|April 4, 2022
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial TumorsDavid S Hong, Marcus O Butler, Russell K Pachynski, et al.
Oncoimmunology|December 15, 2018
Clinical characterization of colitis arising from anti-PD-1 based therapyDaniel Y Wang, Meghan J Mooradian, DaeWon Kim, et al.
Journal for Immunotherapy of Cancer|October 12, 2021
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacyBriana Rose Halle, Allison Betof Warner, Farzana Y Zaman, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.
Kidney International|June 27, 2025
Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor-associated acute interstitial nephritisShruti Gupta, Kavita Mistry, Firasat M Alikhan, et al.
Journal of Translational Medicine|October 29, 2014
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013Paolo A Ascierto, Antonio M Grimaldi, Ana Carrizosa Anderson, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2021
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysisSimone M Goldinger, Kristina Buder-Bakhaya, Serigne N Lo, et al.
Journal for Immunotherapy of Cancer|March 3, 2021
Electrocardiographic features of immune checkpoint inhibitor associated myocarditisDaniel A Zlotoff, Malek Z O Hassan, Amna Zafar, et al.
Journal for Immunotherapy of Cancer|July 6, 2022
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanomaPrachi Bhave, Tasnia Ahmed, Serigne N Lo, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|December 8, 2024
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumorsFlorentia Dimitriou, Marlana M Orloff, Erica C Koch Hein, et al.
Frontiers in Oncology|April 4, 2022
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial TumorsDavid S Hong, Marcus O Butler, Russell K Pachynski, et al.
Oncoimmunology|December 15, 2018
Clinical characterization of colitis arising from anti-PD-1 based therapyDaniel Y Wang, Meghan J Mooradian, DaeWon Kim, et al.
Journal for Immunotherapy of Cancer|October 12, 2021
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacyBriana Rose Halle, Allison Betof Warner, Farzana Y Zaman, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.
Kidney International|June 27, 2025
Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor-associated acute interstitial nephritisShruti Gupta, Kavita Mistry, Firasat M Alikhan, et al.
Journal of Translational Medicine|October 29, 2014
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013Paolo A Ascierto, Antonio M Grimaldi, Ana Carrizosa Anderson, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2021
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysisSimone M Goldinger, Kristina Buder-Bakhaya, Serigne N Lo, et al.
Journal for Immunotherapy of Cancer|March 3, 2021
Electrocardiographic features of immune checkpoint inhibitor associated myocarditisDaniel A Zlotoff, Malek Z O Hassan, Amna Zafar, et al.
Journal for Immunotherapy of Cancer|July 6, 2022
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanomaPrachi Bhave, Tasnia Ahmed, Serigne N Lo, et al.
Pageof 11